Donaldson's Q4 Earnings Beat Estimates, Sales Increase Y/Y

Donaldson Company (DCI) reported strong fourth-quarter fiscal 2025 results, surpassing consensus estimates with adjusted EPS of $1.03 (up 9.6% YoY) and revenues of $981 million (up 4.8% YoY), contributing to full-year EPS of $3.68 on $3.7 billion revenue. Despite a 130 basis point decline in gross margin due to tariff-related inflation, operating profit increased, driven by robust performance in its Life Sciences and Industrial Solutions segments. While the company experienced a decline in operating and free cash flow and an increase in long-term debt, it issued an optimistic fiscal 2026 outlook, projecting adjusted EPS of $3.92-$4.08 and sales growth of 1-5%.

Analysis

Donaldson Company (DCI) delivered strong fourth-quarter fiscal 2025 results, exceeding consensus estimates with a 9.6% year-over-year increase in adjusted EPS to $1.03 and a 4.8% rise in revenue to $981 million. Growth was driven by robust performance in the Life Sciences (+14% YoY) and Industrial Solutions (+8% YoY) segments, while the core Mobile Solutions segment grew a modest 2% due to a significant 20% decline in On-Road business offsetting strength in Off-Road and Aftermarket sales. However, profitability faced headwinds as gross margin contracted by 130 basis points to 34.5%, a decline explicitly attributed to tariff-related inflation. The balance sheet and cash flow statement reveal areas of concern: for the full fiscal year, free cash flow decreased 16.1% to $342.0 million while long-term debt increased from $483.4 million to $630.4 million. This leverage increase coincided with aggressive capital returns, including $465 million in stock repurchases, which outpaced free cash flow generation. Looking ahead, management issued a constructive outlook for fiscal 2026, projecting adjusted EPS growth of 6.5%-10.9% and sales growth of 1-5%, although the forecast for low single-digit growth in the recently high-flying Life Sciences segment suggests some moderation.

Key Decisions for Investors

• While the positive fiscal 2026 guidance for EPS growth of 6.5%-10.9% supports a constructive view, investors should weigh this against the deteriorating cash flow and rising debt profile.
• Investors should closely scrutinize the company's capital allocation strategy, as fiscal 2025 capital returns of $560 million significantly outpaced free cash flow of $342 million, raising questions about the sustainability of such returns without improved cash generation.
• Monitor gross margins for signs of stabilization or improvement, as the 130 basis point contraction due to tariffs represents a key profitability risk that could cap upside if inflation-related cost pressures persist.
• Track segmental performance, particularly whether the Life Sciences division can outperform its conservative 'low single-digit' growth guidance for fiscal 2026, which could provide a significant upside surprise given its recent 14% growth rate.